Home | Accelerate@Babraham | Meet the experts | Keith Blundy

Keith Blundy

CEO, Storm Therapeutics Ltd

Keith joined STORM Therapeutics as CEO in January 2017. Prior to STORM (from 2007), Keith was Chief Executive of Cancer Research Technology Ltd, the commercial arm of Cancer Research UK (CRT), where he drove the development of CRT to become a global leader in the commercialisation of cancer discoveries. He was instrumental in the launch of the £70m Cancer Research Technology Pioneer Fund in partnership with the European Investment Fund (EIF) and BACIT, developed risk sharing drug discovery alliances with AstraZeneca, Teva (formerly Cephalon), Forma, Merck, and MRCT, negotiated the formation of the CRUK – Medimmune antibody therapeutics laboratory and developed CRT’s geographical reach through establishment of CRT Inc. in Boston (USA) and partnership with Cancer Therapeutics Pty in Melbourne, Australia.

After completing a PhD at the John Innes Institute and a post-doctoral Fulbright scholarship in the US on the regulation of plant gene expression, Keith spent ten years managing and commercialising agricultural biotechnology programmes before transitioning to healthcare through business development at CRT. Keith has a BSc and PhD in genetics and an MBA from the London Business School. He was formerly a director of KuDOS Pharmaceuticals Ltd, Mission Therapeutics and Cancer Therapeutics Pty and is currently on the board of Inivata Ltd and chairman of Cizzle Biotech.

Contact us


(+44) 1223 496 000

Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom

Press Enquiries

01223 813 557

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
; ;